Share this article
Share this article
NEW YORK, July 1, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. ( ChemoCentryx or the Company ) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 4, 2021, the U.S. Food and Drug Administration ( FDA ) released a Briefing Document concerning ChemoCentryx s drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis. To support its New Drug Application for avacopan, ChemoCentryx relied primarily upon its Phase III ADVOCATE study. In the Briefing Document, the FDA wrote that [c]omplexities of the study design . . . raise questions about the i
Leitrim County Council are seeking proposals on residential zoned development land and turnkey projects for social housing
leitrimobserver.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leitrimobserver.ie Daily Mail and Mail on Sunday newspapers.
Bragar Eagel & Squire, P C Reminds Investors That Class Action Lawsuits Have Been Filed Against ChemoCentryx, AcelRx, Ocugen, and Tarena and Encourages Investors to Contact the Firm
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc (CCXI)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.